header logo image


Page 664«..1020..663664665666..670680..»

Researchers found a cure for diabetes (in lab mice) – The Next Web

February 27th, 2020 8:43 pm

More than 34 million Americans have diabetes, approximately 10% of the population according to the American Diabetes Association. To date, the most common treatment has been to manage the disease with a carefully controlled diet and regular insulin shots, if needed. But a cure may be on the horizon.

A research team led by Jeffrey Millman at Washington University in St. Louis, Missouri found last year that infusing mice with stem cells could offer a better treatment option.

Building on that research, the same team may have found a cure: at least in lab mice.

Diabetics are characterized by their difficulty producing or managing insulin. This requires careful monitoring, a strict diet, exercise, and expensive insulin shots which many diabetics find themselves rationing due to the cost of drugs in the United States. Insulin is normally produced in the pancreas, but those with diabetes dont produce enough of it. To treat diabetes, many diabetics have to monitor their blood sugar levels, and inject insulin directly into the bloodstream as needed. Millmans treatment foregoes these shots and instead uses beta cells to secrete the insulin for you.

The treatment relies on induced pluripotent stem cells (iPS cells). These cells are essentially a blank slate and can be tricked into becoming almost any other type of cell in the body.

In a new study, the team improved on the technique it had developed last year to produce and introduce these cells into the bloodstream. When converting the stem cells into another type of cell, there are always mistakes and random cells enter into the mix along with the insulin-producing ones. These cells are harmless, but they dont pull their weight.

The more off-target cells you get, the less therapeutically relevant cells you have, Millman told New Atlas. You need about a billion beta cells to cure a person of diabetes. But if a quarter of the cells you make are actually liver cells or other pancreas cells, instead of needing a billion cells, youll need 1.25 billion. It makes curing the disease 25% more difficult.

The new method would rid the sample of those unwanted cells. Millmans team built a process that targeted the cytoskeleton, the structure that gives the cells their shape, and produced not only a higher percentage of effective beta cells, but better functioning ones.

When these new cells were infused into diabetic mice, their blood sugar levels stabilized, leaving them functionally cured of the disease for up to nine months.

Granted, its just an animal trial. The results shouldnt be interpreted as a cure for humans. But its a promising start.

The team plans to continue testing the cells in larger animals, and over longer periods, with their sights set on human clinical trials in the future.

Read next: Smithsonian Institute just released 2.8 million high-quality images for free

Read more:
Researchers found a cure for diabetes (in lab mice) - The Next Web

Read More...

Diabetic Patients Get Ready: An Oral Insulin Capsule That May Soon Be On The Market – Forbes

February 27th, 2020 8:43 pm

Nearly half a billion people worldwide suffer from diabetes.

Many will eventually have no other option but to use insulin. Until now, insulin was only available via injection or an inhaler. One company just took a huge step towards a much-anticipated alternative: an Insulin capsule.

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, just announced unprecedented topline data from the second and final cohort of its Phase 2b trial evaluating the efficacy and safety, at lower dose regimens, of its lead oral insulin capsule, ORMD-0801.

While many huge corporations have spent millions of dollars trying to create an oral insulin pill, none have succeeded so far. This new development, which signals the first commercial oral insulin capsule for the treatment of type 2 and type 1 diabetes, might be the game-changer that revolutionizes the treatment of diabetes.

Established in 2006, with offices in New York and Israel, Oramed has developed a Protein Oral Delivery technology that is based on more than 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

The options of diabetics.

Since insulin was first discovered, it has been impossible to deliver it orally, because of degradation and factors affecting absorbance; since insulin is a protein, the body breaks it down when ingested. The company uses enteric coating and special protection which allows the insulin to stay intact through the GI tract and reach the intestinal wall. Via special absorption enhancers, the insulin can pass through this wall and into the liver, where it starts working. Importantly, it mimics the natural path of insulin in the body, by heading to the liver first.

Although diabetes has spread rapidly, the average person knows very little about living with this chronic condition. In addition to pain, inconvenience, visible scars and dependence, many patients living with diabetes simply cannot afford to keep up with the rising costs of insulin. According to one Washington Post report, because of the skyrocketing prices of insulin, some desperate diabetics are rationing the drug and putting their lives at risk as a result.

Researchers also found that many diabetes patients were cutting back on insulin due to its high cost. Other studies estimate that at least 25 percent of patients with diabetes are not taking the insulin prescribed to them.

Oramed CEO Nadav Kidron is confident that the cost of the pill will be significantly lower (by tens of percent) than the cost of insulin injections.

Nadav Kidron, Oramed CEO.

In addition, treatment with the capsule at all doses demonstrated an excellent safety profile, with no serious drug-related adverse events and no increased frequency of hypoglycemic episodes or weight gain, compared to placebo. The statistically significant efficacy data, says Joel M. Neutel, MD, Principal Investigator of the Phase 2b trial, coupled with a clean safety profile characterized by no reported weight gain, no increase in serious drug-related adverse events, and no hypoglycemia, further support its clinical potential. It further validates the clinical potential of oral insulin to have a highly beneficial impact on the treatment of diabetes worldwide.

A1C levels areakey indicator of diabetes.In this latest trial, patients who were treated with 8 mg of the capsule once daily achievedan observed mean reduction of 1.29% from the baseline anda least square mean reduction of 0.95% from baseline(0.81% placeboadjusted). Patients who had A1C readings above 9% at baseline and received 8 mg of oral insulin once daily experienced a 1.26%placebo adjustedreduction in A1C by week 12.

We are looking forward to discussing with the FDA our planned Phase 3 trial, concludes Kidron. We are additionally very pleased with the progress of our Chinese partners, HTIT, who will also be initiating Phase 3 trials for our oral insulin and might even become the first to reach commercialization."

Read this article:
Diabetic Patients Get Ready: An Oral Insulin Capsule That May Soon Be On The Market - Forbes

Read More...

Escherichia coli and the Progression of Diabetes Mellitus: A Review – Infectious Disease Advisor

February 27th, 2020 8:43 pm

Diabetes mellitus (DM) is one of the leading causes of death globally.1 DM is a metabolic disorder characterized by hyperglycemia resulting from a low level or complete deficiency of insulin hormone.1,2 Insulin, synthesized by the cells of the pancreatic islets of Langerhans, plays a key role in modulating blood glucose levels.1,2 Type 1 DM (T1DM) is triggered by autoimmune destruction of pancreatic cells, which leads to an absolute insulin deficiency,1,2 whereas type 2 DM (T2DM) typically is caused by insulin resistance along with insufficient insulin secretion.1,2

With a rapid rise in incidence during the last 50 years, T1DM is one of the most frequent autoimmune disorders in childhood and adolescence.3,4 T1DM is generally associated with a long prediabetic seroconversion period, during which autoantibodies to antigens of pancreatic cells or insulin are produced.3,4 There are a few known factors that trigger autoimmunity during infancy, such as spontaneous cell death within the -cell population, deposition of islet amyloid polypeptide aggregates, or viral infection that specifically targets pancreatic cells and leads to islet cell death, which contribute to the formation of -cell antigens, activation of dendritic cells, and antigen presentation.3,4 However, the exact etiopathogenesis remains poorly understood.

In general, patients with diabetes are more prone to microbial infections, which have been postulated to have a causal relationship with high blood glucose levels. However, it is little known about the role of therapeutic insulin administration on dissemination of infectious diseases in people with DM.2

Effect of Gut Microbiome

The increase in incidence of T1DM may not be solely a result of genetics and environmental factors, but also that of gut microbiota.3,4 Given the overarching influence of gut bacteria on human health, including its association with the functions of the bodys immune system and intestinal permeability, accumulating data suggest the gut microbiome may contribute to the pathogenesis of T1DM.3,4

The microbiota of the human intestinal tract is composed of bacteria, fungi, and eukaryotic and bacterial viruses (bacteriophages).3,4 Bacteria in the human gut live within surface-associated microbial communities, termed biofilms, which are characterized by the presence of self-produced extracellular matrix and a surface film that protects the microorganisms from the outer environment.3,4 Moreover, several studies have shown that the development of T1DM may be driven by some forms of bacteria.3,4

E coli

Among the aforementioned bacteria, the most common etiologic agent has been found to be Escherichia coli.3,4 Although E coli plays a protector role for the gut microbiome, E coli can affect all organs and systems and is a major cause of extraintestinal infections in patients with diabetes.3,4 E coli is the causative agent for 70% cases of patients with DM with an emphysematous urinary tract infection and in 40% of those with emphysematous cholecystitis.3,4 Moreover, high blood sugar levels have been linked to E colis rapid multiplication and ability to establish more severe form of the infection.3,4 Consequently, individuals with diabetes may be at higher risk for moderate or severe infection-related morbidity.

Association Between E coli and DM

A separate study conducted by Madacki-Todorovic and colleagues presented evidence for the direct effect of insulin on increased metabolic activity of E coli in an association with its biofilm-forming capability.5 Patients with DM are at high risk of developing microbial infections, which are believed to be triggered by the hyperglycemic physiologic status they have and can compromise components of the immune system.5 Pathogenic microorganisms can lead to disease as a result of suppression of the host immune mechanisms. Yet scant evidence has been reported on the role of therapeutic insulin administration on dissemination of infectious diseases in people with DM.

Aside from human insulins influence on the growth kinetic of E coli, little is known about other effects of insulin on E coli in the course of systemic infection, and there is a lack of data on how insulin may affect metabolic activity of this pathogen and its ability to become a biofilm former. Consequently, the researchers of this study investigated the effect of hormone insulin on the expression of enzymatic virulent factors of E coli as the most common pathogen associated with morbimortality in patients with diabetes.5 Three strains of E coli (E coli-C1, E coli-C2, and E coli-C3) with robust biofilm-forming ability, together with nonbiofilm-former E coli strain (E coli-Ref) as the control, were isolated from clinical samples of patients by using conventional microbiologic identification and isolation methods.5

A key defining characteristic of microorganisms such as E coli is their ability to grow and multiply in different environments if they have all necessary nutritive supplements. Therefore, all E coli strains were incubated in growth media at 37 C for different incubation times with the addition of human insulin in dosing concentration of 2.5 U/mL.5 The results demonstrated that insulin administration had a significant stimulatory effect on E coli proliferation of all tested E coli strains, serving as an autoinducer or stimulatory agent for E coli infection and pathogenicity compared with control strains that were not supplemented with insulin and showed a significantly lower proliferation rate at all incubation times.5

Moreover, microbial proteases also play a crucial role in cell viability and virulence status of the microbe, and protease genes are new potential therapeutic targets in treatment of infectious diseases.5 Aspartyl proteinase of E coli is a catalytic type of enzyme that is released from the cell at higher concentration during the infection process of the host. Compared with control strains that were not supplemented with insulin, the presence of insulin also stimulated expression of E coli virulent factor enzyme aspartyl proteinase, which in synergism with human insulin served as signal molecules for bacterial quorum sensing and biofilm formation.5 This study demonstrated that human hormone insulin, even in this low concentration, not only had significant stimulatory effect on proliferation of bacterial cells but also significantly affected metabolic activity of E coli and acted as an autoinducer for biofilm formation.5 Based on these findings, the researcher reasonably identified human insulin as potential risk factor for dissemination of E coli infections and for the increase of related pathogenicity because of its stimulatory effect on the expression of aspartyl proteinase genes.5

A multidrug-resistant bacterium with biofilm-forming capacity can commonly cause devastating complications in patients with DM, including diabetic foot ulcers and diabetic foot infections.5 Results of this study also underline the need for development of alternative catheter materials that will not allow biofilm formation and guidelines in choice of catheters for patients with diabetes.5

Association between E coli and T1DM

A study conducted by Tetz et al revealed that there may be a correlation between a high level of amyloid-producing E coli in the intestinal tract, followed by their depletion resulting from prophage induction and the initiation of autoimmunity, and T1DM progression.3 In humans, pathologic depositions of insoluble amyloid aggregates have been shown to be associated with the development of T1DM, where an increased islet amyloid polypeptide concentration may constitute a risk factor for -cell destruction.3

As the gut microbiota is known to play a role in T1DM, Tetz and colleagues at the Human Microbiology Institute in New York City analyzed data from a prospective longitudinal microbiome cohort study by Kostic et al of 16 children (aged 0-3 years) with human leukocyte antigens (HLA)-susceptibility to T1DM, using an algorithm focusing on amyloid-producing bacteria.3,4 High-throughput shotgun sequencing was performed on the Illumina HiSeq500 platform for microbiota sequencing and processing.3 This analysis revealed an overlooked association between autoimmunity and the dynamics of gut amyloid-producing E coli.3

The findings demonstrated a different, dynamic relationship in children with HLA-conferred susceptibility to T1DM.3 E coli tended to disappear over time in patients with T1DM and patients who were seroconverters, whereas it increased and did not change significantly over time in children without HLA-conferred susceptibility to T1DM.3 E coli depletion was found before the appearance of antibodies, suggesting a role of E coli in disease onset.3 Moreover, their in vitro study revealed a highly immunogenic complex (amyloid curli-DNA composites) released from E coli biofilms upon prophage induction, which triggered the production of type I interferons through the TLR2/9 stimulation of -cells and DCs, and autoimmune cascade through the TLR-2-MyD88-NF-kB pathway. 3

This suggests that a leaky gut allows E coli amyloid-DNA complexes to pass to the lamina propria and trigger autoimmunity and T1DM progression.3 The researchers concluded that that E coli biofilm-derived highly immunogenic amyloid curly-DNA complexes might be involved in the activation of a prodiabetic pathway in children who are at a risk of T1DM. 3

In conclusion, E coli is a notorious pathogen with a broad spectrum of associated illnesses, including the progression of diabetes. These findings suggest that insulin may potentially be a risk factor for increased E coli virulence. Determining the exact role of E coli in the progression of diabetes may lead to novel diagnostics and interventional approaches; however, further detailed studies are required.

References

1. Baena-Diez JM, Penafiel J, Subirana I, Ramos R, Elosua R, Marin-Ibanez A, et al. Risk of cause-specific death in individuals with diabetes: A competing risks analysis. Diabetes Care. 2016;39(11):1987-1995.

2. Suri RS, Mahon JL, Clark WF, Moist LM, Salvadori M, Garg AX. Relationship between Escherichia coli O157:H7 and diabetes mellitus. Kidney International. 2009;75(Suppl 112):S44-S46.

3. Tetz G, Brown SM, Hao Y, Tetz V. Type 1 Diabetes: An association between autoimmunity, the dynamics of gut amyloid producing E. coli and their phages. Scientific Reports. 2019,9:9685.

4. Kostic AD, Gevers D, Siljander H, et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host & Microbe. 2015;17(2):260-273.

5. Madacki-Todorovic K, Eminovic I, Mehmedinovic NI, Ibirisimovic M. Insulin acts as stimulatory agent in diabetes-related Escherichia coli pathogenesis. Int J Diabetes Clin Res. 2018;5(4):098.

The rest is here:
Escherichia coli and the Progression of Diabetes Mellitus: A Review - Infectious Disease Advisor

Read More...

Diabetes symptoms: What is the difference between Type 1 and Type 2 diabetes symptoms? – Express

February 27th, 2020 8:43 pm

What is Type 1 diabetes?

Type 1 diabetes is not caused by an unhealthy diet or poor lifestyle choices, but rather it is an autoimmune condition.

This means your immune system attacks itself instead of protecting your body from disease.

Your body attacks the cells in your pancreas responsible for making insulin, meaning you are unable to produce any of this essential hormone.

While you can live without insulin, it is responsible for glucose (sugar) in our blood entering our cells and fuelling our bodies.

Youre still able to break down carbohydrates and turn it into glucose but no insulin means the glucose cant get into your cells, causing a buildup of glucose in your bloodstream.

If left for a long period of time, high glucose levels in your blood can cause complications with your heart, eyes, feet, and kidneys.

Only eight percent of adults who have diabetes have Type 1, so its much less common than Type 2.

READ MORE:Type 2 diabetes symptoms: Look out for this sign in your nails

The symptoms for both types of diabetes are the same, but it is the speed in which they happen that is different.

With Type 1 diabetes, the symptoms pop up more quickly, so it may be easier to spot and get a diagnosis.

Type 2 symptoms might be less noticeable, since they appear more slowly.

There are more ways to manage Type 2 than Type 1.

Since Type 2 is connected to your health and lifestyle, you are able to exercise and change your diet in order to improve blood sugar levels without medication.

You cannot cure diabetes.

Type 1 is incurable, but research is continuing in the hope to find one.

Type 2 cannot be cured either, but a lot of people are able to get to a stable and normal blood sugar levels without medication and keep it there.

Even if you hold this healthy level, you arent cured- diabetes is an ongoing disease.

See the rest here:
Diabetes symptoms: What is the difference between Type 1 and Type 2 diabetes symptoms? - Express

Read More...

Putting Diabetes Tools ‘in the Pocket’ Improves A1c Control – Medscape

February 27th, 2020 8:43 pm

Patients with type 2 diabetes who were part of a healthcare plan and used a computer and/or app on a mobile device to access a portal (website) with tools for managing diabetes were more adherent with prescription refills and had improved A1c levels, in a 33-month study.

The improvements were greater in patients without prior portal usage who began accessing the portal via a mobile device (smartphone or tablet) app as well as computer, as opposed to a computer only.

And the improvements were greatest in patients with poorly controlled diabetes (A1c >8%) who began accessing the portal by both means.

"Patients with greater clinical need were able to benefit even more from mobile portal access, both in taking their medications more often and in actually improving blood sugar levels," lead author Ilana Graetz, PhD, an associate professor at the Rollins School of Health Policy and Management, Emory University, Atlanta, Georgia, observed in a statement from Kaiser Permanente.

The results show that "patients can use technology to better manage their own care, their medications, and their diabetes," added senior author Mary Reed, DrPH, a research scientist at the Kaiser Permanente Division of Research, Oakland, California.

According to Reed, "This is an example of how the healthcare system, by offering patients access to their own information and the ability to manage their healthcare online, can improve their health."

"Offering this in a mobile-friendly way can give even more patients the ability to engage with their healthcare," she noted. "It literally puts the access to these tools in the patient's own pocket wherever they go."

The study was published online February 19 in JAMA Network Open.

Graetz and colleagues performed a retrospective analysis of data from 111,463 adults with type 2 diabetes who were not receiving insulin but were taking oral diabetes medications and were covered by a healthcare plan with Kaiser Permanente Northern California from April 1, 2015 to December 31, 2017.

Patients could register online for free access to a portal that allowed them to get general health information and see their laboratory test results, as well as securely send and receive messages to and from their healthcare providers, make medical appointments, and request prescription refills.

Study outcomes were change in oral diabetes medication adherence and A1c levels at 33 months.

Patients were a mean age of 64 years and 54% were men.

At baseline, 28% had poor medication adherence (monthly days covered <80%) and 20% had poor glycemic control (A1c >8%).

After 33 months, the proportion of patients who never accessed the diabetes management portal dropped from 35% to 25%, and the proportion who accessed it from both a computer and an app increased from 34% to 62%.

Among patients with no prior portal access who began accessing the portal by computer only, medication adherence increased by 1.16% and A1c dropped by 0.06%.

However, among patients with no prior portal access who began to access it using both a computer and an app, diabetes management improvement was greater: medication adherence increased by 1.67% and A1c dropped by 0.13%.

And among patients with no prior portal usage who had an initial A1c >8.0% and began to access the website by both means, medication adherence increased by 5.09%, equivalent to an added 1.5 medication-adherent days per month, and A1c levels fell by 0.19%.

There was also "a more modest but still statistically significant increase" of about 0.5 added medication-adherent days per month in patients with lower initial A1c levels who began accessing the portal both ways.

"While medication adherence measured by medication dispensed cannot guarantee which medications were actually used by patients," the authors write, "our findings of concurrent improvements in [A1c] levels confirm physiological improvements in diabetes control."

"Convenient access to portal self-management tools through a mobile device could significantly improve diabetes management," they conclude.

The study was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases. The authors have reported no relevant financial relationships.

JAMA Netw Open. 2020;3:e1921429. Full text

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

Read more from the original source:
Putting Diabetes Tools 'in the Pocket' Improves A1c Control - Medscape

Read More...

Diabetes, CVD Tied to Worse Prognosis for COVID-19 Infection – Medscape

February 27th, 2020 8:43 pm

Indications so far are that people with diabetes and other chronic medical conditions, such as cardiovascular disease (CVD), will have a worse prognosis if they become infected with COVID-19, the novel coronavirus that has emerged from China.

There is also evidence that diabetes may increase risk for infection from COVID-19 two- to threefold, independently of other medical problems, such as CVD.

Although more detailed analysis is needed to show a clearly defined connection between conditions such as diabetes and worse prognosis with COVID-19, the statistics suggest that this virus hits hardest among the most vulnerable, ie, the elderly and people with multiple medical problems, especially those with diabetes of long duration that has not been well controlled.

"The message we want to emphasize is that emergencies unmask vulnerabilities in diabetes. The old and the sick are the most vulnerable," Juliana C. N. Chan, MD, told Medscape Medical News in an interview.

Chan is director of the Hong Kong Institute of Diabetes and Obesity at the Chinese University of Hong Kong.

Chan and other experts are therefore calling for diabetes patients, those with CVD, and patients with other chronic medical conditions to be extra vigilant in their efforts to avoid contact with the virus, although they also note that individual responses vary greatly.

In past infectious disease outbreaks, including severe acute respiratory syndrome (SARS) and H1N1 flu, people with diabetes were at increased risk for severe illness and death.

"I don't think it's an overstatement to say that people with diabetes...are at higher risk of developing COVID-19, because the data are suggestive," noted Chan, although she cautioned that longer-term research will give a much clearer picture.

Chan was a senior coauthor on a study published last month in Diabetologia, as reported by Medscape Medical News, that found that mortality rates among people with diabetes in Hong Kong have plummeted in recent years except for young people, who may be more likely to have poorly controlled diabetes.

And importantly within the context of the COVID-19 outbreak although in that study deaths from most conditions such as CVD and cancer decreased among people with diabetes, deaths from pneumonia among people with diabetes remained about the same.

In serious cases of infection, the COVID-19 virus invades the cells that line the respiratory tract and lungs and enters the mucus, causing pneumonia. Severe lung damage from pneumonia can result in acute respiratory distress syndrome (ARDS), which in turn can cause septic shock.

ARDS and septic shock are the main causes of death from COVID-19.

So far, Hong Kong has had only 70 confirmed cases of COVID-19, although the first Hong Kong resident to die from the virus was a 39-year-old man with diabetes. That death was soon followed by a second death a 70-year-old man with diabetes and other medical problems, including high blood pressure and kidney disease.

"Our message is to ask people with diabetes to do things early in order to protect themselves and reduce their risk of having problems if anything happens," Chan emphasized to Medscape.

Although the mechanism of this increased susceptibility remains unclear, research suggests that high blood glucose levels may lead to reduced functioning of the immune system.

As of February 25, COVID-19 had infected about 80,000 people and had caused almost 2500 deaths worldwide.

Although the vast majority of these infections and deaths have been in China, there are now pockets of infection in Iran, Italy, Japan, and South Korea, as well as handfuls of cases in many other countries.

The World Health Organization (WHO) yesterday stopped short of calling the outbreak a pandemic but stressed that the status could change at any time.

Although COVID-19 appears to be highly transmissible, only a small percentage of people seem to develop severe illness, and an even smaller number die from the infection.

A recent study of 44,672 confirmed COVID-19 cases that had been reported through February 11 and that were analyzed by the Chinese Centers for Disease Control and Prevention (CCDC) shows that 80.9% of people in China who have been diagnosed with COVID-19 have had mild illness.

So far, the overall case fatality rate (CFR) in China is 2.3% less than previous coronavirus outbreaks caused by SARS (CFR: 9.6%) and Middle East respiratory syndrome (MERS) (CFR: 34.4%).

That said, because COVID-19 has infected far more people than SARS or MERS, the newest coronavirus on the block has already claimed many more lives.

This in turn raises the question: who is most at risk for severe illness and death from COVID-19?

Case fatality rates vary by factors such as age, sex, underlying medical conditions, and geography. Outside Hubei province in China, the epicenter of the outbreak, the CFR may be as low as 0.4%, compared to 2.9% within the province.

So far, for all age groups, the highest CFR is among people aged 80 years or older, at 14.8%. CFRs have been higher in people with other medical conditions than in healthy people.

CVD and diabetes top that list, at case fatality rates of 10.5% and 7.3%, respectively, compared to 0.9% for people without any prior disease, according to the aforementioned latest CCDC report.

Before publication of this report, two relatively small case series of patients who had been hospitalized for COVID-19 in Wuhan also suggested that older men with underlying medical problems, especially CVD and diabetes, are more likely to develop severe illness from the virus.

However, experts caution that for COVID-19 and similar infections, several factors may skew the data, making interpretation tricky.

"Cases that are identified tend to be in patients that have more severe illness, compared to younger, healthier individuals who just stay home and don't seek medical care," said Preeti N. Malani, MD, an infectious disease specialist and chief health officer at the University of Michigan Medical School, Ann Arbor.

"This is also the case with individuals who are sick enough to be hospitalized. There are more people with more chronic conditions, including diabetes [among hospitalized individuals]," Malani told Medscape via email.

"In general, diabetes can be a marker of other chronic health conditions like heart disease as well as obesity, which might contribute to the increased risk of infection," Malani added.

"Diabetes is also much more common with age and will continue to be a marker of poor outcomes for [all of] these reasons," she said.

All of this makes it tricky to tease out diabetes' individual contribution to infection risk.

"The proportion in which each medical condition contributes to...risk of infection is hard to dissect out," explained Andrea Luk, MBChB, FHKCP, FHKAM.

Luk is an associate professor at the Chinese University of Hong Kong and is the other senior coauthor of the study in Diabetologia.

"Certainly a person with both diabetes and cardiovascular disease would have more risk than someone with diabetes and good glucose control and without any other comorbidities," she continued.

But because every person with diabetes is different, it is important to consider the whole package, she stressed.

Whether someone with diabetes succumbs to infection has a lot to do with glycemic control, diabetes duration, and diabetes-related comorbid conditions, such as heart disease, kidney disease, and stroke, as well as their age, weight, and whether they smoke.

Chan further clarified: "We have to judge this case by case. You cannot apply it across the board to all people with diabetes. A person with well-controlled diabetes is very different from someone with poorly controlled diabetes. They have a different set of risk factors and complications."

While awaiting more detailed analysis, Chan, Luk, and Malani all suggest common-sense measures for patients with diabetes, CVD, and other chronic conditions: staying up to date with vaccinations, avoiding large crowds, frequent hand washing, avoiding touching eyes or mouth (the so-called T-zone), and wearing face masks in areas where COVID-19 is prevalent.

People with symptoms should also wear a face mask to avoid spreading infection to others.

Malani added, "Although there is a lot of focus and concern about COVID-19, this has [also] been a terrible year for seasonable flu. I recommend flu shots, especially for...patients with diabetes."

She also suggested being thoughtful about travel.

"This may not be a good time for nonessential travel to Asia, as the situation there is evolving. COVID-19 risk is still low, depending on where you go, but the risk of disrupted travel is real," she noted.

Even without an emergency such as COVID-19, Chan and Luk say they cannot stress highly enough the importance of optimal glucose control for people with diabetes.

"People with diabetes or other chronic conditions should be extra vigilant about protecting themselves from infection," Luk reiterated.

They should also have a lower threshold for seeking care if they feel they are developing symptoms of infection, she noted.

"It's hard to tell at the beginning whether it's influenza or COVID-19 because they present similarly," she said.

Chan, Luk, and Malani have disclosed no relevant financial relationships.

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

Read more from the original source:
Diabetes, CVD Tied to Worse Prognosis for COVID-19 Infection - Medscape

Read More...

FDA Clears InPen Diabetes Management System for Fixed Dosing and Meal Estimation – PRNewswire

February 27th, 2020 8:43 pm

Companion Medical today confirmed that it has received clearance from the FDA for its InPen bolus calculator for fixed dosing and meal estimation. The new bolus calculator takes into consideration each user's current glucose level and active insulin - the calculation of the amount of insulin still lowering glucose from previous bolus doses, removing the guesswork from insulin dosing. This is the first time a clearance like this has been issued for those with Type 1 or Type 2 insulin-dependent diabetes who administer a fixed amount of insulin for meals or deliver a dose based on the approximate size of their planned meal, as opposed to individual carb estimations. These new capabilities allow InPen to help the majority of patients using multiple daily injections, regardless of their personal insulin regimen.

"Our goal since launching in 2017 has been to make insulin therapy simpler for all people with diabetes - not just the most engaged or advanced. We do this by letting the InPen system do most of the heavy lifting and ease the burden," said Sean Saint, CEO and founder of Companion Medical. "Similar to the first InPen dose calculator, which has been a game-changer for those of us who count carbs, this new FDA clearance for users on fixed-dose or meal estimation therapy finally offers a simple, yet advanced solution to those people living with insulin-dependent diabetes who are not expert carb counters."

"The biggest predictor of better control amongst people living with diabetes is the number of insulin doses per day. Patients without a dose calculator with active insulin tracking have been taught for years to dose at least four hours apart because of the dangers of insulin stacking - this allows for only a maximum of three or four doses per day," said Mike Mensinger, CTO and co-founder at Companion Medical. "With the new calculator modes, InPen provides an experience consistent with these patients' current therapies, while adjusting recommendations automatically based on their current glucose level and factoring in active insulin to safely allow correction of high blood glucose between meals."

"This feature allows insulin pen users to be met where they are in their therapy," said Janice MacLeod who leads Companion Medical's clinical advocacy efforts. "The clinicians I have spoken to are excited about this feature for their patients, in particular those with Type 2 diabetes who inject insulin. Not all patients are able or wish to, count carbs for every meal, and the option of correction doses informed by InPen's active insulin tracking is incredibly useful in helping users avoid stacking their insulin and minimizing their risk of low glucose."

The InPen system, which includes a smart pen and Bluetooth connected app, helps calculate insulin doses, issue dose reminders, track active insulin and send reports to caregivers. InPen is available in the U.S. by prescription only. The app is available for download on the Apple App Store and Google Play. For more information, visit http://www.companionmedical.com.

About Companion Medical Companion Medical develops easy-to-use, affordable diabetes technology focused on advanced insulin delivery and real-time actionable insights. The company's flagship product, InPen, is the first FDA-cleared smart insulin pen and mobile app-based diabetes management system providing people with diabetes and healthcare providers with essential data to optimize insulin regimens.

SOURCE Companion Medical, Inc.

Home

Go here to read the rest:
FDA Clears InPen Diabetes Management System for Fixed Dosing and Meal Estimation - PRNewswire

Read More...

This is to seal it as Tandem Diabetes Care, Inc. (TNDM) shares are up 61.59% from its 52-week low – The InvestChronicle

February 27th, 2020 8:43 pm

At the end of the latest market close, Tandem Diabetes Care, Inc. (TNDM) was valued at $77.94. In that particular session, Stock kicked-off at the price of $77.72 while reaching the peak value of $79.97 and lowest value recorded on the day was $75.46. The stock current value is $76.53.

Tandem Diabetes Care, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $91.65 on 02/20/20, with the lowest value was $47.36 for the same time period, recorded on 04/18/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Tandem Diabetes Care, Inc. shares are logging -16.50% during the 52-week period from high price, and 61.59% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $47.36 and $91.65.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.5 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Tandem Diabetes Care, Inc. (TNDM) recorded performance in the market was 28.38%, having the revenues showcasing 11.84% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.62B, as it employees total of 653 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 66.39, with a change in the price was noted +21.78. In a similar fashion, Tandem Diabetes Care, Inc. posted a movement of +39.78% for the period of last 100 days, recording 1,517,027 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for TNDM is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Tandem Diabetes Care, Inc. in the period of last 50 days is set at 55.32%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 28.98%. In the last 20 days, the companys Stochastic %K was 50.33% and its Stochastic %D was recorded 68.74%.

Bearing in mind the latest performance of Tandem Diabetes Care, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 28.38%. Additionally, trading for the stock in the period of the last six months notably improved by 9.56%, alongside a boost of 54.89% for the period of the last 12 months. The shares increased approximately by 10.45% in the 7-day charts and went down by -15.00% in the period of the last 30 days. Common stock shares were driven by 11.84% during last recorded quarter.

Original post:
This is to seal it as Tandem Diabetes Care, Inc. (TNDM) shares are up 61.59% from its 52-week low - The InvestChronicle

Read More...

Unique diabetes and infection network launched – United News of India

February 27th, 2020 8:43 pm

More News27 Feb 2020 | 11:51 PM

New Delhi, Feb 27 (UNI) Aam Aadmi Party on Thursday night suspended its councillor Tahir Hussain after he was booked by the Delhi Police over the charges of murder of Intelligence Bureau staffer Ankit Sharma.

New Delhi, Feb 27 (UNI) Aam Aadmi Party (AAP) councillor Tahir Hussain was booked by the Delhi Police on Thursday over the charges of murder of Intelligence Bureau staffer Ankit Sharma.

New Delhi, Feb 27 (UNI) As many as 112 evacuees including 36 foreigners, who arrived from the Coronavirus epicenter Wuhan in China, were taken to makeshift quarantine facility of Indo Tibetan Border Polices(ITBP) at Chhawla here on Thursday.

New Delhi, Feb 27 (UNI) The Congress on Thursday demanded Home Minister Amit Shah's resignation over the 'failure' of National Investigating Agency (NIA) to file a chargesheet against the accused of Pulwama attack, a claim which the NIA has refuted.

New Delhi, Feb 17 (UNI) Amid the media reports of Pulwama Attack case accused getting bail by the Special Court, the National Investigation Agency (NIA) on Thursday clarified that Yusuf Chopan alias Mehraj-ud-din Chopan was never arrested in the Pulwama attack case that killed 40 jawan of Central Reserve Police Force on February 14, 2019.

See the original post here:
Unique diabetes and infection network launched - United News of India

Read More...

Research on intermittent fasting shows health benefits – National Institute on Aging

February 27th, 2020 8:42 pm

Evidence from decades of animal and human research points to wide-ranging health benefits of intermittent fasting, according to an NIA-conducted review of the research, published in the New England Journal of Medicine. Still, more research is needed to determine whether intermittent fasting yields benefits or is even feasible for humans when practiced over the long term, such as for years.

Intermittent fastingis an eating pattern that includes hours or days of no or minimal food consumption without deprivation of essential nutrients. Commonly studied regimens include alternate day fasting, 5:2 intermittent fasting (fasting two days each week), and daily time-restricted feeding (such as eating only during a six-hour window).

Hundreds of animal studies and scores of human clinical trials have shown that intermittent fasting can lead to improvements in health conditions such as obesity, diabetes, cardiovascular disease, cancers and neurological disorders. The evidence is less clear for lifespan effects. Animal studies have shown mixed results, with sex, food composition, age and genetics among the factors that influence longevity. Human trials have mainly involved relatively short-term interventions and so have not provided evidence of long-term health effects, including effects on lifespan.

The review authors are Rafael de Cabo, Ph.D., of NIAs Intramural Research Program (IRP), and Mark P. Mattson, Ph.D., formerly of NIAs IRP and currently a neuroscientist at the Johns Hopkins University School of Medicine.

Although intermittent fasting often results in reduced calorie consumption, weight loss is not the main driver of the health benefits observed in preclinical and clinical studies, according to the authors. Rather, the key mechanism is metabolic switching, in which fasting triggers the body to switch its source of energy from glucose stored in the liver to ketones, which are stored in fat.

Ketone bodies are not just fuel used during periods of fasting, the authors wrote. They are potent signaling molecules with major effects on cell and organ functions.

Ketogenesis, or the increase of ketones in the bloodstream, initiates activity in a variety of cellular signaling pathways known to influence health and aging. This activity enhances the bodys defenses against oxidative and metabolic stress and initiates the removal or repair of damaged molecules. The impact of ketogenesis carries over into the non-fasting period and can improve glucose regulation, increase stress resistance and suppress inflammation.

Repeated exposure to fasting periods results in lasting adaptive responses that confer resistance to subsequent challenges, the authors explain. The broad-spectrum benefits include not only disease resistance but also improved mental and physical performance.

The authors acknowledge impediments to widespread adoption of intermittent fasting: the ingrained practice in developed nations of three meals a day plus snacks (along with the ready availability and marketing of food), the discipline required to shift to a new eating pattern and the lack of physician training on intermittent fasting interventions. The authors suggest that clinicians who prescribe intermittent fasting encourage their patients to adopt a gradual, phased-in schedule in consultation with a dietitian or nutritionist.

In addition to the question of intermittent fastings long-term effects in humans, the authors point to two other areas requiring further research. Studies are needed to determine whether this eating pattern is safe for people at a healthy weight, or who are younger or older, since most clinical research so far has been conducted on overweight and middle-aged adults. In addition, research is needed to identify safe, effective medications that mimic the effects of intermittent fasting without the need to substantially change eating habits.

This review article and many of the research studies cited within were supported by NIA.

Reference: De Cabo R and Mattson MP. Effects of intermittent fasting on health, aging, and disease. New England Journal of Medicine. 2019;381(26):2541-2551. doi: 10.1056/NEJMra1905136.

Read more from the original source:
Research on intermittent fasting shows health benefits - National Institute on Aging

Read More...

Dogs Wanted for Massive Study on Aging in Canines – The Bark

February 27th, 2020 8:42 pm

Almost 80,000 dogs have been nominated to participate in a new nationwide study on dog aging since registration began last fall, but theres still time for your dog to become part of the pack.

We know from previous work done with dog owners that they are motivated to help their dogs live longer, healthier lives, but the response has been positively overwhelming, saidAudrey Ruple, a veterinary epidemiologist and assistant professor of One Health Epidemiology in the Purdue UniversityCollege of Health and Human SciencesDepartment of Public Health.

TheDog Aging Projectwill look at dogs from all breeds and mixes from across the nation. This is the first major longitudinal study involving dogs, and it's scheduled to last at least 10 years.

Dogs are good models for humans, said Ruple, who is one of more than 40 scientists and researchers participating in the study. They have similar genetics, share our environment, and they also have similar diseases and health issues. We will be asking, How do dogs age healthfully? in order to help better understand how we can age healthfully, too.

Sign up for our newsletter and stay in the know.

Dogs of all age ranges, breeds and sizes are eligible to participate. Owners can goonlinefor more information and to register their dogs. The most popular breeds submitted so far for the study are Labrador retriever, golden retriever, German shepherd, dachshund, Australian shepherd, poodle, chihuahua, shih tzu, boxer and Yorkshire terrier.

Once enrolled, owners will need to complete surveys about their dogs health and lifestyle.Dogs must go through their regular annual examination with their veterinarian. If a dog is assigned to a specific study group, owners may be sent a kit for the veterinarian to collect blood, urine or other samples during the annual visit. Participation is voluntary, and there is no cost to participate.

Ruple said the group also is trying to find the nation's oldest dog.

Dogs have been nominated from all 50 states. The states with the most nominated canines are California, Washington, Texas, Florida, New York, Illinois, Pennsylvania, North Carolina, Colorado and Ohio. States with the least nominations are North Dakota, South Dakota, Wyoming, Delaware and Mississippi.

The group has had nine dogs nominated that were 24 years old, as well as nine other dogs that were 23 years old.

All dogs registered will be eligible to participate in various studies.

Researchers hope to find out more details on how factors like an individuals genome, proteome, microbiome, demographics and environmental factors such as chemical exposures and noise pollution impact health and longevity.

Ruple said one goal of the study is to not just improve the health and longevity of dogs, but also extend those findings to improve human health.

By studying aging in dogs, we hope to learn how to better match human health span to life span so that we can all live longer, healthier lives, Ruple said.

Funding for the Dog Aging Project comes from the National Institute of Aging, a part of the National Institutes of Health, as well as from private donations.

The rest is here:
Dogs Wanted for Massive Study on Aging in Canines - The Bark

Read More...

Car T-cell therapy: The future fifth pillar of cancer treatment – The Irish Times

February 27th, 2020 8:41 pm

Revolutionary Car T-cell therapy is set to become the fifth pillar of cancer treatment and is already showing dramatic results in the successful treatment of blood cancers.

Prof Owen Smith is a consultant paediatric haematologist who has dedicated his 35-year career to researching and treating cancer in children and young adolescents. Smith, who is based at Childrens Health Ireland at Crumlin hospital, is a specialist in stem cell transplantation. Over the years, he has seen big advances in cancer treatments but few have excited him as much as Car T-cell therapy which is showing huge potential as a pioneering treatment for blood and other challenging cancers.

In a nutshell, Car (chimeric antigen receptor) T-cell therapy is a form of immunotherapy that uses the patients own immune cells to recognise and attack cancer. It involves drawing blood from the patient, isolating the T-cells within it and genetically altering and multiplying them in a lab. The end product is transfused back into the patient where the Car T-cells bind to an antigen or structural molecule on the cancer cells and kills them.

Car T-cells or Cars for short, are like sniper fire that target the cancer rather than blanket bombing it, explains Prof Smith. They cause much less toxicity than chemotherapy and have much better results and remission rates.

Cars therapy has been in gestation since the early 1980s with the first-generation treatment becoming available around 2010.

To date, about 2,200 Cars have been completed in the US, while in Europe the number is about 800 and growing fast. There are now two second generation Car T products licensed for three types of blood cancer and Prof Smith says: We now have hope with these relapse/refractory blood cancers where only a few years ago, we had none.

Prof Smith was working in Royal Free Hospital in London (one of the UKs major Car T therapy centres today) in the 1980s when the therapeutic potential of T-cells, which was initially discovered in Israel, was first being realised. It became clear through some good connected thinking that it was the T-cells that were having a very important effect on cure in patients with CML (chronic myeloid leukaemia), he says. Around the same time there were papers coming in from the States with similar results so the concept was beginning to gather momentum.

The question became: could you take T-cells from a donor and give them to people who were relapsing and put them into remission? Things began to crystallise in the late 80s/early 90s as T cells were recognised as immune effector cells that were very good at killing cancer, especially in patients with CML who were relapsing after stem cell transplantation.

Then people began wondering if we could use the end of the molecule the so-called antigen binding part of an antibody and link it to the T-cell receptor and put it into T-cells to see if that would give an even better result. What eventually followed between 2010 and 2014 were a number of first generation Car T-cell studies that showed it was very effective in some patients with haematological malignancies and in those with acute lymphoblastic and chronic lymphocytic leukaemia in particular. Since then there have been 10 big studies with second generation Cars that have also proved its efficacy, says Prof Smith.

Acute lymphoblastic leukaemia is the most common form of blood cancer in children and Prof Smith sees about 50 cases a year here. Unfortunately, if this cancer relapses, particularly during or shortly after chemotherapy, it usually becomes resistant to further treatment and the children can also no longer tolerate it. The only option up to now has been palliative care, but Cars is a lifeline that can alter this outcome.

Second generation Car T-cell activity can push around 90 per cent of children into remission and once you get them into remission you have time to get them into prime clinical condition to give them a stem cell transplant and cure them that way, says Prof Smith. In the adult population, about 20 cases a year of non-Hodgkins lymphoma would be suitable for this therapy.

Weve known for a long time that the immune system is important in someone developing cancer, Prof Smith adds. So, for example when a persons T-cells are knocked out by something like HIV, they typically have an increased risk of developing lymphoid malignancies. The immune system can also be tricked into not recognising when a cancer develops and undergoes metastatic spread. This immune activation therapy can unmask this camouflaging of the cancer resulting in regression.

One of the challenges with the Cars is that they can become lost in the body and lose their persistence. When this happens the person usually relapses. We are now looking at different combinations of Cars and using two or three of them on the one cell to prevent relapse, says Prof Smith.

This is a massively evolving field and one of these exponential technologies you hear about from time to time. Whats really encouraging it that its now being pushed out to treat other types of high-risk solid tumours that currently have dismal survival rates such as metastatic non-small cell lung cancer, pancreatic cancer, triple negative breast cancer, ovarian cancer, brain tumours and neuroblastomas in children. Its opening up a totally different treatment pathway for cancer.

Prof Smith acknowledges that Cars, like many innovative cancer treatments, is expensive at about 300,000 per commercially produced treatment. But he points out that as its use becomes more widespread prices will drop and that if the total costs of conventional treatments are added up the economic argument for its use is compelling. Yes, its costly but some recent health economic data from the USA is suggesting it may not be as costly as it first appears, he says. Specifically, repeated chemotherapy, the cost of regular hospital admissions due to relapse, trips to intensive care, blood product support and anti-bacterial, anti-fungal and anti-viral therapies all with very little return in terms of clinical outcome.

Prof Smith adds that Car T therapy is set to become the fifth pillar of cancer treatment alongside surgery, chemotherapy, radiation and targeted therapy and that whats happening now is just the start of the Car T revolution. The next phase will be using them in combination with checkpoint inhibitors (another arm of immunotherapy) and the third generation of Cars will have greater efficacy and less toxicity, he says.

Prof Smith is low key about his personal achievements but in addition to saving the lives of countless children under his care, he also has a distinguished research record and his work has been widely published and acknowledged internationally. He was to the forefront of a major breakthrough in the intervention and treatment of meningitis in the 1980s and he is a strong believer in robust peer-reviewed clinical trials, which he believes are one of the most effective ways of establishing a cure for any disease.

Owen Smith is professor of Paediatric and Adolescent Medicine at UCD, honorary Regius Professor of Physic (1637) at Trinity College and academic lead to the Childrens Hospital Group. He is also a principal investigator at the National Childrens Research Centre and Systems Biology Ireland at University College Dublin and national clinical programme lead for children and adolescents/young adults with cancer. In 2015 he was awarded a CBE by Queen Elizabeth for his life-long dedication to treating cancer in children.

Prof Smith is a speaker at the international BioPharma Ambition 2020 event which is being held in Dublin Castle on March 3rd and 4th.

Excerpt from:
Car T-cell therapy: The future fifth pillar of cancer treatment - The Irish Times

Read More...

Policy and public health: all the decisions we can’t see – PMLiVE

February 27th, 2020 8:41 pm

Lets be honest, January was a bad month for healthcare news coming out of China.

For starters, at the end of December, a Chinese court sentenced He Jiankui to three years in prison for operating an illegal medical practice, which includes using a fake ethical review certificate and misleading participants about a studys risks, and also violating an ethics guidance from 2003 that barred the reproductive use of research embryos.

You may remember Dr Jiankui as the individual who made the worlds first genetically edited babies by recruiting couples in which the man was HIV positive but the woman was not, as part of an effort to create embryos with a genetic mutation that made the couples offspring protected from the virus.

Esteemed bioethicists and scholars, such as Josephine Johnston from the Hastings Center that produces books, articles and other publications on ethical questions in medicine, science and technology that help inform policy, practice and public understanding, as well as Robin Lovell-Badge, a stem cell biologist at the Francis Crick Institute, have both acknowledged that He Jiankuis work straddled a line that might have got them in hot water in both the US and the UK.

In fact, Lovell-Badge said in a statement distributed by the United Kingdoms Science Media Centre that both prison and a fine would have been the likely penalties if someone had done what [He Jiankui] did in the UK.

And then, in early January, China informed the world about a deadly new coronavirus that has been causing severe respiratory illness and death among its citizens.

As of 6 February, in China there were over 28,000 confirmed cases and 565 people have died there; in addition there were more than 220 confirmed cases outside China and there has been one death in the Philippines.

On 26 January, the New York Times wrote: The outbreak has drawn fresh attention to Chinas animal markets, where the sale of exotic wildlife has been linked to epidemiological risks. The Wuhan virus is believed to have spread from one such market in the city. The SARS outbreak nearly two decades ago was also traced back to the wildlife trade.

These two scenarios highlight an important aspect of public health and health policy: complex decisions that require almost real-time response are only as good as the information upon which those decisions are based.

In the case of He Jiankui, many countries have policies and laws in place against germline gene editing. But because the court proceedings, documentation and testimony in this case have not been made public, it is impossible to know the details surrounding the events that may have facilitated this rogue scientists behaviour.

And because we dont have those details, implementing new health policy to prevent recurrences of this situation remains difficult. Not impossible, but difficult. Some will argue that US and UK laws are expansive enough and the penalties imposing enough on their own merits that we need not fret about a single scientists actions in a universally agreed upon opaque scientific ecosystem.

Others will argue that the scientific communitys overwhelmingly negative response and outrage will discourage this from happening again. I disagree.

And in the coronavirus situation, the same New York Times article went on to say: Conclusive evidence about how this outbreak started is lacking. Although officials in Wuhan first traced it to a seafood market, some who have fallen ill never visited the market.

'Researchers have also offered disparate explanations about which animals may have transmitted the virus to humans. Chinas record doesnt help. During the SARS epidemic in 2002 and 2003, officials covered up the extent of the crisis, delaying the response. The Chinese government has promised far more transparency this time, and the World Health Organization (WHO) has praised its cooperation with scientists.

Im sure we all feel better that a non-partisan agency like the WHO has authenticated the cooperation of the Chinese scientific community in 2020 but the issue is far more complex.

We need to understand the larger social and cultural issues that may be driving the underlying causes of these deadly illnesses. And in order to do that, the Chinese governments openness to the rest of the worlds questions and, ultimately, its willingness to revise public policy to reflect a greater harmonisation for global public health will be put to the test.

This is not a China issue. Its a transparency issue. Whether its the reporting of a measles outbreak in America or the promulgationof information on Ebola cases in West Africa, we are all responsible because the world needs more transparency.

Follow this link:
Policy and public health: all the decisions we can't see - PMLiVE

Read More...

Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD – Yahoo Finance

February 27th, 2020 8:41 pm

Patient Analyses and Safety Data Continue to Underscore Positive Impact of KD025 in cGVHD

Pre-NDA Meeting with FDA Planned for March 2020; Topline Results of Primary Analysis to be Announced in Q2 2020

NEW YORK, NY / ACCESSWIRE / February 23, 2020 / Kadmon Holdings, Inc. (KDMN) today announced expanded results from the previously reported interim analysis of ROCKstar (KD025-213), its ongoing pivotal trial of KD025 in chronic graft-versus-host disease (cGVHD). The data were presented today in the oral latebreaker session at the 2020 Transplantation & Cellular Therapy (TCT) Meetings.

As announced in November 2019, KD025 met the primary endpoint of Overall Response Rate (ORR) at the study's planned interim analysis, two months after completion of enrollment. KD025 showed statistically significant and clinically meaningful ORRs of 64% with KD025 200 mg once daily (95% Confidence Interval (CI): 51%, 75%; p<0.0001) and 67% with KD025 200 mg twice daily (95% CI: 54%, 78%; p<0.0001). In the expanded KD025-213 dataset presented today, ORRs were consistent with the previously reported interim analysis across key subgroups, including in patients with four or more organs affected by cGVHD (n=69; 64%), patients who had prior treatment with ibrutinib (n=45; 62%) and patients who had prior treatment with ruxolitinib (n=37; 62%). Three patients achieved a Complete Response. Responses were observed in all affected organ systems, including in organs with fibrotic disease. KD025 has been well tolerated: adverse events were consistent overall with those expected to be observed in cGVHD patients receiving corticosteroids, and no apparent increased risk of infection was observed. Additional secondary endpoints, including duration of response, corticosteroid dose reductions, Failure-Free Survival, Overall Survival and Lee Symptom Scale reductions continue to mature and will be available later in 2020.

"KD025 has been well tolerated and has already demonstrated high response rates in patients with severe and complex cGVHD after a median of five months of follow-up," said Corey Cutler, MD, MPH, FRCPC, Associate Professor of Medicine, Harvard Medical School; Medical Director, Adult Stem Cell Transplantation Program, Dana-Farber Cancer Institute and a KD025-213 study investigator and Steering Committee member.

"We are extremely pleased with the interim outcomes of this pivotal trial of KD025 in cGVHD, which track closely our findings from our earlier Phase 2 study. KD025 achieved robust response rates across all subgroups of this difficult-to-treat patient population, who had a median of four prior lines of therapy, and 73% of whom had no response to their last line of treatment," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We plan to meet with the FDA for a pre-NDA meeting in March 2020 and to announce topline results from the primary analysis of this trial in Q2 2020."

At the TCT Meetings, Kadmon also presented long-term follow-up data from KD025-208, its ongoing Phase 2 study of KD025 in cGVHD (Abstract #15205). These data were recently presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in December 2019.

About the ROCKstar (KD025-213) Trial

KD025-213 is an ongoing open-label trial of KD025 in adults and adolescents with cGVHD who have received at least two prior lines of systemic therapy. Patients were randomized to receive KD025 200 mg once daily or KD025 200 mg twice daily, enrolling 66 patients per arm. Statistical significance is achieved if the lower bound of the 95% CI of ORR exceeds 30%.

While the ORR endpoint was met at the interim analysis, which was conducted as scheduled two months after completion of enrollment, topline data from the primary analysis of the KD025-213 study, six months after completion of enrollment, will be reported in Q2 2020. Full data from the primary analysis will be submitted for presentation at an upcoming scientific meeting.

About KD025

KD025 is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates immune response as well as fibrotic pathways. In addition to cGVHD, KD025 is being studied in an ongoing Phase 2 clinical trial in adults with diffuse cutaneous systemic sclerosis (KD025-209). KD025 was granted Breakthrough Therapy Designation and Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of patients with cGVHD who have received at least two prior lines of systemic therapy.

Story continues

About cGVHD

cGVHD is a common and often fatal complication following hematopoietic stem cell transplantation. In cGVHD, transplanted immune cells (graft) attack the patient's cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. Approximately 14,000 patients in the United States are currently living with cGVHD, and approximately 5,000 new patients are diagnosed with cGVHD per year.

About Kadmon

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Our clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Forward Looking Statements

This press release contains forward-looking statements. Such statements may be preceded by the words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe, China, Japan and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel (xx) the potential benefits from any of our product candidates being granted orphan drug or breakthrough designation; (xxi) the future trading price of the shares of our common stock and impact of securities analysts' reports on these prices; and/or (xxii) other risks and uncertainties. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact Information

Ellen Cavaleri, Investor Relations646.490.2989ellen.cavaleri@kadmon.com

SOURCE: Kadmon Holdings, Inc.

View source version on accesswire.com: https://www.accesswire.com/577466/Kadmon-Announces-Expanded-Results-of-Interim-Analysis-of-Pivotal-Trial-of-KD025-in-cGVHD

Go here to see the original:
Kadmon Announces Expanded Results of Interim Analysis of Pivotal Trial of KD025 in cGVHD - Yahoo Finance

Read More...

Global Synthetic (Cultured) Meat Market : Full In-depth Analysis by Top Key Players, Regional Outlook, Latest Trend and Forecast to 2024 – Nyse Nasdaq…

February 26th, 2020 8:47 pm

The Synthetic (Cultured) Meat report delineates the key features rendering the growth of the global Synthetic (Cultured) Meat Market. The research study is a prolific account of macroeconomic and microeconomic factors boosting the growth of the global Synthetic (Cultured) Meat market. It also exhibits the market valuation within the calculated time period, thereby helping market players to make appropriate changes in their approach towards attaining growth and sustaining their position in the industry.

The global Synthetic (Cultured) Meat report outlines the latest market trends in the related field. The global Synthetic (Cultured) Meat market is segmented according to product, application, and geography. Each segment is evaluated in great detail so that players can focus on high-growth driving areas of the global Synthetic (Cultured) Meat market and further assist in burgeoning their sales growth. The report comprises the global revenue [USD Million] and size [kMT] of the market. The research report evaluates the global market development with the help of different methodical and analytical tools.

Click Here To Access The Sample Report: https://www.acquiremarketresearch.com/sample-request/318625/

Market Segment as follows

Synthetic (Cultured) Meat market competition by top Manufacturers: Aleph Farms, Finless Foods, Future Meat Technologies, Integriculture Inc., JUST Inc., SuperMeat, Appleton Meats, Avant Meats Company Limited, Balletic Foods, Biofood Systems LTD., Bluenalu, Inc., Cell Farm FOOD Tech/Granja Celular S.A.

By the product type, the market is primarily split into: Soy Protein Type, Animal Stem Cell Synthesis Type, Others

Global Synthetic (Cultured) Meat Market by Application Segments: Meatballs, Burgers, Sausages, Hot dogs, Nuggets

In addition, the major product types and segments Synthetic (Cultured) Meat along with their sub-segments or application of the global market also are enclosed within the scope of the report. The study discusses the details of major market players, their strategies, and other critical factors. Porters five forces are considered for understanding the growth of the global market. The global Synthetic (Cultured) Meat market is segmented on the basis of applications, product categories, and regionally. It furthermore highlights all product categories in the consumer application segment.

To Get This Report At Beneficial Rates: https://www.acquiremarketresearch.com/discount-request/318625/

Reasons for Buying this Report1. This report furnishes a detailed analysis for changing competitive dynamics and keeps you abreast of other leading competitors.2. It provides a futuristic perspective on different factors driving or restraining market growth.3. It throws light on the six-year forecast assessed on the basis of how the market is projected to grow.4. The report abstract helps in understanding the key product segments and their future.5. An in-depth analysis of changing competition dynamics6. It assists you in undertaking informed business decisions by having complete insights of market and making in-depth analysis of market segments.

Based on regions, the market is classified into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. The study will provide detailed qualitative and quantitative information on the above-mentioned segments for every region and country covered under the scope of the study.

The Middle East and Africa (GCC Countries and Egypt)North America (the United States, Mexico, and Canada)South America (Brazil etc.)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The Synthetic (Cultured) Meat Research Report offers insight study on:1. The assessed growth rate together with Synthetic (Cultured) Meat size & share over the forecast period 2020-2024.2. The key factors estimated to drive the Synthetic (Cultured) Meat Market for the projected period 2020-2024.3. The leading market vendors and what has been their Synthetic (Cultured) Meat business progressing strategy for success so far.4. Important trends driving the growth possibility of the Synthetic (Cultured) Meat Market.

To Know More About The Assumptions in This Market Report: https://www.acquiremarketresearch.com/industry-reports/synthetic-cultured-meat-market/318625/

Why Buy This Report?

The research report provides a complete analysis of the global Synthetic (Cultured) Meat market to help players create powerful growth strategies and consolidate their position in the industry. The report presents a complete mapping of the market participants and the competitive landscape. Information on important sustainability strategies adopted by key companies, along with their impact on market growth and competition has been provided in this report. All players can use the report to prepare themselves to face future market challenges and further strengthen their position in the global market.

To conclude, the Synthetic (Cultured) Meat market report outlines information on the key geographies, market landscapes alongside the production and consumption analysis, supply and demand analysis, market growth rate, besides the future forecast, etc. This report also provides SWOT and PEST analysis, investment feasibility and return analysis.

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Original post:
Global Synthetic (Cultured) Meat Market : Full In-depth Analysis by Top Key Players, Regional Outlook, Latest Trend and Forecast to 2024 - Nyse Nasdaq...

Read More...

What’s coming down the pike in the dental profession? – Dentistry IQ

February 26th, 2020 8:45 pm

Maryp | Dreamstime.com

A plethora of dental research is underway in the US as well as globally. Some of these advancements will come to fruition and be commercially available, and some will die on the vine. There are innovations in essentially every dental discipline, with breakthroughs that have the potential to enhance oral health in ways we couldnt imagine in the past.

The impact of artificial intelligence (AI) will increase in the future. AI is already at work in hospitals to diagnose cancer and anticipate trends in health care. AI will have a significant effect in the dental profession on a daily basis, from evaluating images for pathology, to prosthetics and systemic care, among many others. AI promises to increase efficiency in dental practice by facilitating faster diagnosis, predictive analytics, and autocharting.

Other areas of research and development include gene therapy and stem cells. Research is underway using gene therapy to restore salivary function in patients who have undergone radiation treatment, which could be a tremendous improvement in health for these individuals. The negative impact of dry mouth extends far beyond the discomfort associated with inadequate or complete lack of saliva. It has a significant effect on the quality of life of the individual and the health of the oral cavity. The ability to restore salivary function could be life-changing for many people.

Other initiatives involve transformative research in periodontics, specifically agents operating on the host response and others applied to the diseased periodontal pockets. Some of the research on host-response therapies involves agents that repair the immune system dysfunction responsible for tissue degeneration. This is accomplished by using minute quantities of an agent that creates a gradient, resulting in the mobilization of regulatory cells that dampen down the inflammatory response, which is responsible for the tissue destruction that accompanies periodontal disease.

Some of the research focused on the clinical application of agents into periodontal pockets does not involve antimicrobial therapies, but rather are regenerative in nature. Preparation of the affected area is simple and quick, followed by application of the regenerative agent. Clinical trials have demonstrated significant pocket depth reduction and bone regeneration. If these results are consistent and reproducible, a complete paradigm shift in the treatment of periodontitis could occurone that is essentially noninvasive, quick, and inexpensive.

There are a number of disruptive technologies in various stages of development that will dramatically change the manner in which we practice dentistry. Some of these changes will mirror developments in the medical profession, such as gene therapy and influencing the immunoinflammatory system to reduce tissue damage, which ultimately benefits the individuals oral and overall health.

Editor's note: Would you like to learn more about the latest in oral-systemic research?Write to Dr. Richard Nagelbergabout topics youve read about in this blog or submit items youd like to see covered here.

Previous blog: Updates on periodontal disease pathogens and the heart

Editor's note: This article originally appeared in Breakthrough Clinical, aclinical specialties newsletter from Dental Economics and DentistryIQ. Read more articles at this link.

Richard H. Nagelberg, DDS, has practiced general dentistry in suburban Philadelphia for more than 30 years. He is a speaker, advisory board member, consultant, and key opinion leader for several dental companies and organizations. He lectures on a variety of topics centered on understanding the impact dental professionals have beyond the oral cavity. Contact Dr. Nagelberg atrnagelberg@orapharma.com.

Read the original here:
What's coming down the pike in the dental profession? - Dentistry IQ

Read More...

On the Road to 3-D Printed Organs – The Scientist

February 26th, 2020 8:45 pm

For years, scientists have predicted that 3-D printingwhich has been used it to make toys, homes, scientific tools and even a plastic bunny that contained a DNA code for its own replicationcould one day be harnessed to print live, human body parts to mitigate a shortage of donor organs. So far, researchers also used 3-D printing in medicine and dentistry to create dental implants, prosthetics, and models for surgeons to practice on before they make cuts on a patient. But many researchers have moved beyond printing with plastics and metalsprinting with cells that then form living human tissues.

No one has printed fully functional, transplantable human organs just yet, but scientists are getting closer, making pieces of tissue that can be used to test drugs and designing methods to overcome the challenges of recreating the bodys complex biology.

A confocal microscopy image showing 3-Dprinted stem cells differentiating into bone cells

The first 3-D printer was developed in the late 1980s. It could print small objects designed using computer-aided design (CAD) software. A design would be virtually sliced into layers only three-thousandths of a millimeter thick. Then, the printer would piece that design into the complete product.

There were two main strategies a printer might use to lay down the pattern: it could extrude a paste through a very fine tip, printing the design starting with the bottom layer and working upward with each layer being supported by the previous layers. Alternatively, it could start with a container filled with resin and use a pointed laser to solidify portions of that resin to create a solid object from the top down, which would be lifted and removed from the surrounding resin.

When it comes to printing cells and biomaterials to make replicas of body parts and organs, these same two strategies apply, but the ability to work with biological materials in this way has required input from cell biologists, engineers, developmental biologists, materials scientists, and others.

So far, scientists have printed mini organoids and microfluidics models of tissues, also known as organs on chips. Both have yielded practical and theoretical insights into the function of the human body. Some of these models are used by pharmaceutical companies to test drugs before moving on to animal studies and eventually clinical trials. One group, for example, printed cardiac cells on a chip and connected it to a bioreactor before using it to test the cardiac toxicity of a well-known cancer drug, doxorubicin. The team showed that the cells beating rate decreased dramatically after exposure to the drug.

However, scientists have yet to construct organs that truly replicate the myriad structural characteristics and functions of human tissues. There are a number of companies who are attempting to do things like 3-D print ears, and researchers have already reported transplanting 3-D printed ears onto children who had birth defects that left their ears underdeveloped, notes Robby Bowles, a bioengineer at the University of Utah. The ear transplants are, he says, kind of the first proof of concept of 3-D printing for medicine.

THE SCIENTIST STAFF

Bowles adds that researchers are still a ways away from printing more-complex tissues and organs that can be transplanted into living organisms. But, for many scientists, thats precisely the goal. As of February 2020, more than 112,000 people in the US are waiting for an organ transplant, according to the United Network for Organ Sharing. About 20 of them die each day.

For many years, biological engineers have tried to build 3-D scaffolds that they could seed with stem cells that would eventually differentiate and grow into the shapes of organs, but to a large extent those techniques dont allow you to introduce kind of the organization of gradients and the patterning that is in the tissue, says Bowles. There is no control over where the cells go in that tissue. By contrast, 3-D printing enables researchers with to very precisely direct the placement of cellsa feat that could lead to better control over organ development.

Ideally, 3-D printed organs would be built from cells that a patients immune system could recognize as its own, to avoid immune rejection and the need for patients to take immunosuppressive drugs. Such organs could potentially be built from patient-specific induced pluripotent stem cells, but one challenge is getting the cells to differentiate into the subtype of mature cell thats needed to build a particular organ. The difficulty is kind of coming together and producing complex patternings of cells and biomaterials together to produce different functions of the different tissues and organs, says Bowles.

To imitate the patterns seen in vivo, scientists print cells into hydrogels or other environments with molecular signals and gradients designed to coax the cells into organizing themselves into lifelike organs. Scientists can use 3-D printing to build these hydrogels as well. With other techniques, the patterns achieved have typically been two-dimensional, Eben Alsberg, a bioengineer at the University of Illinois, tells The Scientist in an email. Three-dimensional bioprinting permits much more control over signal presentation in 3D.

So far, researchers have created patches of tissue that mimic portions of certain organs but havent managed to replicate the complexity or cell density of a full organ. But its possible that in some patients, even a patch would be an effective treatment. At the end of 2016, a company called Organovo announced the start of a program to develop 3-D printed liver tissue for human transplants after a study showed that transplanted patches of 3-D printed liver cells successfully engrafted in a mouse model of a genetic liver disease and boosted several biomarkers that suggested an improvement in liver function.

Only in the past few years have researchers started to make headway with one of the biggest challenges in printing 3-D organs: creating vasculature. After the patches were engrafted into the mouses liver in the Organovo study, blood was delivered to it by the surrounding liver tissue, but an entire organ would need to come prepared for blood flow.

For any cells to stay alive, [the organ] needs that blood supply, so it cant just be this huge chunk of tissue, says Courtney Gegg, a senior director of tissue engineering at Prellis Biologics, which makes and sells scaffolds to support 3-D printed tissue. Thats been recognized as one of the key issues.

Mark Skylar-Scott, a bioengineer at the Wyss Institute, says that the problem has held back tissue engineering for decades. But in 2018, Sbastian Uzel, Skylar-Scott, and a team at the Wyss Institute managed to 3-D print a tiny, beating heart ventricle complete with blood vessels. A few days after printing the tissue, Uzel says he came into the lab to find a piece of twitching tissue, which was both very terrifying and exciting.

For any cells to stay alive, [the organ] needs that blood supply, so it cant just be this huge chunk of tissue.

Courtney Gegg, Prellis Biologics

Instead of printing the veins in layers, the team used embedded printinga technique in which, instead of building from the bottom of a slide upwards, material is extruded directly into a bath, or matrix. This strategy, which allows the researchers to print free form in 3-D, says Skylar-Scott, rather having to print each layer one on top of the other to support the structure, is a more efficient way to print a vascular tree. The matrix in this case was the cellular material that made up the heart ventricle. A gelatin-like ink pushed these cells gently out of the way to create a network of channels. Once printing was finished, the combination was warmed up. This heat caused the cellular matrix to solidify, but the gelatin to liquify so it could then be rinsed out, leaving space for blood to flow through.

But that doesnt mean the problem is completely solved. The Wyss Institute teams ventricle had blood vessels, but not nearly as many as a full-sized heart. Gegg points out that to truly imitate human biology, an individual cell will have to be within 200 microns of your nearest blood supply. . . . Everything has to be very, very close. Thats far more intricate than what researchers have printed so far.

Due to hurdles with adding vasculature and many other challenges that still face 3-Dprinted tissues, laboratory-built organs wont be available for transplant anytime soon. In the meantime, 3-D printing portions of tissue is helping accelerate both basic and clinical research about the human body.

Emma Yasinski is a Florida-based freelance reporter. Follow her on Twitter@EmmaYas24.

More:
On the Road to 3-D Printed Organs - The Scientist

Read More...

Hyperbaric chamber therapy: Im under a lot of pressure and I love it! – The Guardian

February 26th, 2020 8:45 pm

I wonder what the pedalo does as I slip into a waffle robe Im at Bellecell, a central London molecular-wellness clinic that offers hyper-personalised science-based solutions to health this place could be a Bond villains laboratory on the moon.

I am standing in a hushed, blue-lit underground brick tunnel with Kubrick-white furnishings and so many fascinating toys: EMS suits, laser IVs, and what looks like an exercise bike built into a love boat, with a vacuum for your legs.

As distracting as these things are, I am here to try something specific: a hyperbaric oxygen chamber. I am fascinated by these things. Culturally, they have long been signifiers of megalomania, detachment and anxiety. Michael Jackson had one in his house, which isnt a great recommendation. The Olympian swimmer Michael Phelps is another fan. But what do these chambers actually do? Do you have to be called Michael to use one?

I climb into a plastic body bag in my hospital booties. Hyperbaric oxygen therapy involves breathing pure oxygen in a pressurised environment. The structure is a semi-circular cage with comfortable bedding, surrounded by thick plastic walls. Once I am inside, a technician inflates the bag. I am basically inside a balloon, which will be maintained at constant pressure, as I breathe 100% oxygen through a mask.

Hyperbaric chambers are mostly used to treat gas gangrene, carbon monoxide poisoning and the bends, while the medical uses of oxygen include wound-healing and reducing the risk of infection. Many people report feeling energised afterwards. I have some oral swelling following dental work, and am interested to see if that goes down.

For some, the close confinement and constant sound of pressurisation will be a recipe for a panic attack. For me, it is heaven. I am what you might call a claustrophile. I have always loved climbing into cupboards and corners, making dens and closing a door on the world. I fantasise about Japanese capsule hotels. Now, I lie and watch a zip close above me. There is a hissing noise. I adjust my oxygen mask and observe star-headed thumb screws being turned to calibrate the pressure. The gauge crawls upwards, my ears are getting stuffy. I swallow as it hits 4psi, equivalent to a depth of nine feet under water. Gazing at ambient blue through a hatch to the outside world, I imagine Im much deeper, packed into a nuclear missile on the undercarriage of a submarine. I am in my happy place.

The use of oxygen for performance-enhancement is mostly misunderstood. The effects of inhaling it are extremely short-lived. Athletes are often seen huffing cans of oxygen at the touchline, but science indicates that this is a mostly meaningless activity. Pressure makes all the difference. Under pressure, oxygen is dissolved in larger quantities in the blood plasma itself, not just the red blood cells. That means a much higher amount of the gas is transported into tissues that need it for healing, in theory mobilising stem cell release to repair the body quickly. It is definitely promising; the catch is, you would probably need a few treatments to see the benefit. At 160 an hour, post-workout muscle soreness probably isnt reason enough.

I thoroughly enjoy the experience for its own sake. Lulled by the pressure and soft lighting outside, I fall into a deep, restorative nap. After an hour, I emerge as wobbly as a newborn. I dont feel supercharged, admittedly. I feel drowsy, and absolutely starving. Im assured this is normal. I do feel astonishingly relaxed, though. The swelling inside my mouth reduces significantly over the next day, too, for which I can probably thank the chamber.

I would totally have one of these in my house. I miss the missile, but cant afford to go back. Instead, Im cursed to walk these normobaric streets, breathing 21% oxygen like everyone else, dreaming of when I had less freedom to move.

Walter White, eat your heart out Could I recreate the effect with hydrogen peroxide, bakers yeast and a tarp over the bath?

Wellness or hellness? Airs and graces. 5/5

Follow this link:
Hyperbaric chamber therapy: Im under a lot of pressure and I love it! - The Guardian

Read More...

Doctors Are Injecting This Naturally-Derived Substance to Restore Hair Thicknessand Its Not PRP – NewBeauty Magazine

February 26th, 2020 8:44 pm

The most emotional issue my patients have is hair loss, says New York dermatologist Cheryl Karcher, MD below a jaw-dropping before-and-after photo shared to her Instagram page. On the left half of the photo shared is a young womans exposed hairlinethe hair is so thin and sparse, the entire scalp is visible wherever your eye is drawn. On the right side of the photo, the same woman, but with an almost unbelievable amount of thicker hair, and, somehow, a sense of renewed confidence.

The secret? A little thing called nanofat.

In the past we only had PRP to offer that had to be done three times or more. Sometimes it would work, sometimes it didnt. Now we have nanofat hair restoration, which needs to be done just once, and is much more effective way to treat hair loss and grow hair, explains Dr. Karcher.

You May Also Like: How Low Level Laser Therapy Actually Works to Thicken Hair

So what is nanofat? According to Dr. Karcher, its derived from our own adipose tissue, whereas the ever popular PRP is derived from our blood. Nanofat includes adipose-derived stromal vascular fraction, which contains stem cells as well as growth factors. PRP contains the growth factors released from platelets in the blood, she adds. The procedure itself involves extracting anywhere from 20 to 40 millilitersof fat, usually from the abdomen, then processing it through mechanical filters, before injecting.

Like PRP, the possibilities of what nanofat can help with doesnt stop at the hairline. After the nanofat is processed to the point where there is no fat left, only stem cells and growth factors, it is injected into the scalp, the face, the neck, the decollete, or to improve sun damage, skin pigmentation, decrease wrinkles, and of course grow hair, says Dr. Karcher.

When nanofat is used for hair restoration, Dr. Karcher says she first injects the nanofat, then injects the patients PRP on top of it to act as a fertilizer for the nanofat. Perhaps the best part? Theres little to no painDr. Karcher says the most pain patients feel is during the PRP injections, so the scalp is numbed topicallyand no downtime. When nanofat is used on the face, chest or other areas, Dr. Karcher warns there may be some downtime of erythema and swelling or bruising. If injected for [skin] rejuvenation via microneedling the downtime is only about 48 hours.

While Dr. Karcher has seen unparalleled results from nanofat hair restoration, it is only ideal for patients who have some hair still present on the scalppatients who are completely bald may not be ideal candidates for the procedure. The only time I ever use PRP for hair restoration now is in a patient that doesnt have enough fat to harvest. The nanofat is just one treatment and the results seem to be superior. However, as La Jolla, CA plastic surgeon Robert Singer, MD notes, there is no safety or efficacy data surrounding nanofat treatment as of press time.

Sign up to receive our newsletter

Read more:
Doctors Are Injecting This Naturally-Derived Substance to Restore Hair Thicknessand Its Not PRP - NewBeauty Magazine

Read More...

Rheumatoid Arthritis Associated With Increased Risk for Depression – Rheumatology Advisor

February 26th, 2020 8:43 pm

Resultsfrom 2 longitudinal cohort studies conducted in South Korea indicate asignificantly increased risk for depression among patients with rheumatoidarthritis (RA), with women and those >30 years of age displaying the highestrates. This is according to an article published in Rheumatology.

Investigatorsabstracted data from the Korean Health Insurance Review and Assessment Service National Sample Cohort (HIRA-NSC) from the years 2002-2013. The HIRA-NSC is apopulation-based cohort established by the National Health Insurance Service ofSouth Korea. HIRA-NSC queries demographics, health, and diagnostic data from >1million individuals randomly selected from South Koreas National HealthInsurance Database.

The present analyses included data from 114,369,638 medical claims filed by 1,125,691 patients. Patients with depression and/or RA were identified through their respective International Statistical Classification of Diseases version 10 (ICD-10) codes. Two studies were designed. Study I matched patients with depression 1:4 with cohort members without depression. Study matched patients with RA 1:4 with cohort members without RA. Matching in both studies was performed for age group, sex, income bracket, and region of residence. Cox proportional hazards models were used to calculate hazard ratios (HRs) for depression and RA in each study. HR calculations were adjusted for number of comorbidities.

StudyI enrolled a total of 38,087 patients with depression and 152,348 individualsin a control group. A greater proportion of the patients with depression(n=1260; 0.7%) had a diagnosis of RA compared with the control group (n=883;0.6%) (P =.02). However, the HR for RA was not significantly elevated inthe depression group compared with the control group.

StudyII enrolled a total of 7385 patients with RA and 29,540 individuals in acontrol group, of whom 408 (5.5%) and 1246 (4.3%) had a diagnosis of depression,respectively (P <.001). Patients with RA had significantly increasedrisk for depression compared to those in the control group without RA (HR,1.20; 95% CI, 1.07-1.34; P =.002). In subgroup analyses, patients withRA over 30 years of age had the greatest HRs for depression compared with theircontrol subgroups.

Specifically,patients with RA aged 30-59 years (HR, 1.17; 95% CI, 1.01-1.36; P =.036)and patients 60 years (HR, 1.29; 95% CI, 1.08-1.55; P =.006) hadsignificantly elevated risk for depression compared to controls in the same agebrackets. Women with RA, unlike men, also displayed significantly higherdepression risk compared with controls of the same gender (HR, 1.19; 95%,1.05-1.35; P =.006).

Theseresults suggest that while RA increases the risk for depression, this associationis not bidirectional. Women with RA and patients >30 years were particularlysusceptible to depression. Of note, data on RA and depression severity were notavailable, nor were data on smoking, alcohol consumption, or physical activity.As such, analyses may not have accounted for all possible factors contributing todepression. Even so, the elevated HRs for depression observed among RAsubgroups emphasize the need for mental health care access for patients withRA.

Reference

Kim SY, Chanyang M, Oh DJ, Choi HG. Association between depression and rheumatoid arthritis: two longitudinal follow-up studies using a national sample cohort [published online November 19, 2019]. Rheumatology (Oxford). doi:10.1093/rheumatology/kez559

Read more from the original source:
Rheumatoid Arthritis Associated With Increased Risk for Depression - Rheumatology Advisor

Read More...

Page 664«..1020..663664665666..670680..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick